A preliminary investigation on the incidence of HBV-associated B-NHL and its clinical characteristics

Lan Yukang; Qi Xiaoying; Gui Xien; Zhuang Ke

doi:10.13406/j.cnki.cyxb.003255

您当前的位置：

首页 >

文章列表页 >

A preliminary investigation on the incidence of HBV-associated B-NHL and its clinical characteristics

Clinical research | 更新时间：2025-10-21

- A preliminary investigation on the incidence of HBV-associated B-NHL and its clinical characteristics
- Journal of Chongqing Medical University Vol. 48, Issue 6, Pages: 673-678(2023)
- 作者机构：
  
  1.武汉科技大学医学院,武汉 430065
  2.武汉科技大学附属普仁医院感染科,武汉 430081
  3.武汉大学中南医院感染科,武汉 430072
  4.武汉大学动物实验中心/ABSL-III实验室,武汉 430072
- 作者简介：
- 基金信息：
- DOI：10.13406/j.cnki.cyxb.003255
  CLC： R512.6
- Received：20 July 2022，
  
  Revised：2023-02-28，
  
  Accepted：16 March 2023，
  
  Published：28 June 2023
- 稿件说明：
移动端阅览
兰雨康,戚小英,桂希恩,等.乙型肝炎病毒相关性B细胞非霍奇金淋巴瘤的发生率及其临床特点的初步探讨[J].重庆医科大学学报,2023,48(6):673-678.

Lan Yukang,Qi Xiaoying,Gui Xien,et al.A preliminary investigation on the incidence of HBV-associated B-NHL and its clinical characteristics[J].Journal of Chongqing Medical University,2023,48(6):673-678.
兰雨康,戚小英,桂希恩,等.乙型肝炎病毒相关性B细胞非霍奇金淋巴瘤的发生率及其临床特点的初步探讨[J].重庆医科大学学报,2023,48(6):673-678. DOI： 10.13406/j.cnki.cyxb.003255.

Lan Yukang,Qi Xiaoying,Gui Xien,et al.A preliminary investigation on the incidence of HBV-associated B-NHL and its clinical characteristics[J].Journal of Chongqing Medical University,2023,48(6):673-678. DOI： 10.13406/j.cnki.cyxb.003255.

摘要

目的

了解乙型肝炎病毒（hepatitis B virus，HBV）感染对B细胞非霍奇金淋巴瘤（B-cell non-Hodgkin's lymphoma，B-NHL）发生和临床特点的影响。

方法

对照分析非霍奇金淋巴瘤（non-Hodgkin's lymphoma，NHL）患者中乙型肝炎病毒表面抗原（hapatitis bsurface antigen，HBsAg）的携带率及HBV感染状态，比较不同类型B-NHL患者HBsAg阳性率差异及HBsAg阳性弥漫性大B细胞淋巴瘤（diffuse large B-cell lymphoma，DLBCL）与HBsAg 阴性DLBCL的临床特征、化疗反应和2年生存率。

结果

共纳入597例NHL患者为NHL组，其中B-NHL 461例，T细胞非霍奇金淋巴瘤103例。B-NHL患者HBV感染率（17.1%）明显高于对照组（5.7%），差异有统计学意义（

=0.003）。T细胞非霍奇金淋巴瘤患者HBsAg阳性率（10.7%）与对照组（5.7%）无统计学差异（

=0.796）。对影响351例DLBCL患者总生存率的单因素分析结果显示，女性、年龄≥60岁、HBsAg阳性、肝功能异常、血清乳酸脱氢酶（lactate dehydrogenase，LDH）升高、Ann Arbor期Ⅲ~Ⅳ期以及国际预后指数（international prognostic index，IPI）评分3~5分是不利因素（均

Ｐ

0.05），而获得缓解是有利因素。Cox 回归分析显示患者年龄、HBsAg状态、Ann Arbor分期、治疗反应是影响患者预后的独立危险因素。与HBsAg阴性DLBCL比较，HBsAg阳性DLBCL患者发病年龄更轻（

=0.017），IPI评分较高（

=0.036）、Ann Arbor分期较晚（

=0.001）。HBsAg阳性DLBCL患者化疗有效率（完全缓解+部分缓解）和2年生存率显著低于HBsAg阴性DLBCL患者（

=0.026，

=0.031）。但2组乳酸脱氢酶升高率和脾脏受累率无显著差异。

结论

HBsAg阳性患者可能有更高的风险患B-NHL，且HBV可能对B-NHL的临床特征和预后有负面影响。HBV不仅增加B-NHL的风险，还可加重病情，降低化疗效果，影响患者的远期预后。

Abstract

Objective

To investigate the prevalence of HBsAg in B-cell non-Hodgkin’s lymphoma（B-NHL） and the effect of hepatitis B virus（HBV） infection on the clinical features of B-NHL.

Methods

The carrier rate of hapatitis bsurface antigen（HBsAg） and hepatitis B infection status in patients with non-Hodgkin’s lymphoma（NHL） were analyzed，and the differences in HBsAg positivity rate and HBsAg positive diffuse large B-cell lymphoma（DLBCL），chemotherapy response and 2-year survival rate of HBsAg positive DLBCL and HBsAg negative DLBCL were compared.

Results

A total of 597 eligible NHL patients were enrolled as the NHL group，including 461 B-NHL patients and 103 T-cell non-Hodgkin’s lymphoma（T-NHL） patients. HBV infection rate in B-NHL patients（17.1%） was significantly higher than that in the control group（5.7%）（

=0.003）. However，there was no signif

icant difference in the HBsAg positive rates of T-NHL patients（10.7%） as compared with the control group（5.7%）（

=0.796）. Univariate analysis of the overall survival rate of 351 DLBCL patients showed that female，≥ 60 years old，HBsAg positive，abnormal liver function， elevated serum lactate dehydrogenase（LDH），Ann Arbor stage III–IV and International Prognostic Index（IPI） scores of 3–5 were unfavorable factors（all

0.05），while remission was a favorable factor. Cox regression analysis showed that patient age，HBsAg status，Ann Arbor stage， and response to treatment were independent risk factors affecting patient prognosis. Compared with HBsAg negative DLBCL，HBsAg positive DLBCL patients were younger at onset（

=0.017）， with higher IPI scores（

=0.036），and at later Ann Arbor stage（

=0.001）. The effective rate of chemotherapy（complete remission + partial remission） and the 2-year survival rate of patients with HBsAg positive DLBCL were significantly lower than those of patients with HBsAg negative DLBCL（

=0.026，

=0.031）. However，there were no significant differences in LDH elevation rate and spleen involvement rate between the two groups.

Conclusion

HBsAg positive patients may be at higher risk for B-NHL，and HBV may negatively affect the clinical features and prognosis of B-NHL. HBV not only increases the risk of B-NHL，but also aggravates the disease， reduces the effect of chemotherapy， and affects the long-term prognosis of patients.

关键词

Keywords

references

Armitage JO ， Gascoyne RD ， Lunning MA ， et al . Non-Hodgkin lymphoma [J ] . Lancet ， 2017 ， 390 （ 10091 ）： 298 - 310 .

Miranda-Filho A ， Piñeros M ， Znaor A ， et al . Global patterns and trends in the incidence of non-Hodgkin lymphoma [J ] . Cancer Causes Control ， 2019 ， 30 （ 5 ）： 489 - 499 .

Skrabek P ， Turner D ， Seftel M . Epidemiology of non-Hodgkin lymphoma [J ] . Transfus Apher Sci ， 2013 ， 49 （ 2 ）： 133 - 138 .

Dalia S ， Suleiman Y ， Croy DW ， et al . Association of lymphomagenesis and the reactivation of hepatitis B virus in non-Hodgkin lymphoma [J ] . Cancer Control ， 2015 ， 22 （ 3 ）： 360 - 365 .

Seto WK ， Lo YR ， Pawlotsky JM ， et al . Chronic hepatitis B virus infection [J ] . Lancet ， 2018 ， 392 （ 10161 ）： 2313 - 2324 .

GROUP IW . Biological agents. Volume 100 B. A review of human carcinogens [J ] . IARC Monogr Eval Carcinog Risks Hum ， 2012 ， 100 （ Pt B ）： 1 - 441 .

An J ， Kim JW ， Shim JH ， et al . Chronic hepatitis B infection and non-hepatocellular cancers：a hospital registry-based，case-control study [J ] . PLoS One ， 2018 ， 13 （ 3 ）： e0193232 .

Wang CY ， Xia B ， Ning QY ， et al . High prevalence of hepatitis B virus infection in patients with aggressive B cell non-Hodgkin's lymphoma in China [J ] . Ann Hematol ， 2018 ， 97 （ 3 ）： 453 - 457 .

Su TH ， Liu CJ ， Tseng TC ， et al . Chronic hepatitis B is associated with an increased risk of B-cell non-Hodgkin's lymphoma and multiple myeloma [J ] . Aliment Pharmacol Ther ， 2019 ， 49 （ 5 ）： 589 - 598 .

王保峰，胡红霞 . HBV阴性与阳性非霍奇金淋巴瘤患者的临床特征分析 [J ] . 国际检验医学杂志， 2020 ， 41 （ 5 ）： 616 - 619 .

Wang BF ， Hu HX . Analysis of clinical features of HBV-negative and positive non-Hodgkin's lymphoma [J ] . Int J Lab Med ， 2020 ， 41 （ 5 ）： 616 - 619 .

Engels EA ， Cho ER ， Jee SH . Hepatitis B virus infection and risk of non-Hodgkin lymphoma in South Korea：a cohort study [J ] . Lancet Oncol ， 2010 ， 11 （ 9 ）： 827 - 834 .

Fujimoto K ， Endo T ， Nishio M ， et al . Complete remission of splenic marginal zone lymphoma after an acute flare-up of hepatitis B in a hepatitis B virus carrier [J ] . Int J Hematol ， 2009 ， 90 （ 5 ）： 601 - 604 .

Huang CE ， Yang YH ， Chen YY ， et al . The impact of hepatitis B virus infection and vaccination on the development of non-Hodgkin lymphoma [J ] . J Viral Hepat ， 2017 ， 24 （ 10 ）： 885 - 894 .

Koot AWA ， Visscher AP ， Huits RMHG . Remission of splenic marginal zone lymphoma in a patient treated for hepatitis B：a case of HBV-associated lymphoma [J ] . Acta Clin Belg ， 2015 ， 70 （ 4 ）： 301 - 303 .

Mansoor MS ， Wolfsohn DM . Resolution of small bowel follicular lymphoma with treatment of concomitant hepatitis B [J ] . J Clin Gastroenterol ， 2015 ， 49 （ 10 ）： 885 - 887 .

Lemaitre M ， Brice P ， Frigeni M ， et al . Hepatitis B virus-associated B-cell non-Hodgkin lymphoma in non-endemic areas in Western Europe：clinical characteristics and prognosis [J ] . J Infect ， 2020 ， 80 （ 2 ）： 219 - 224 .

Anderson LA ， Pfeiffer R ， Warren JL ， et al . Hematopoietic malignancies associated with viral and alcoholic hepatitis [J ] . Cancer Epidemiol Biomarkers Prev ， 2008 ， 17 （ 11 ）： 3069 - 3075 .

Amin J ， Dore GJ ， O'Connell DL ， et al . Cancer incidence in people with hepatitis B or C infection：a large community-based linkage study [J ] . J Hepatol ， 2006 ， 45 （ 2 ）： 197 - 203 .

Liu J ， Yang HI ， Lee MH ， et al . Serum levels of hepatitis B surface antigen and DNA can predict inactive carriers with low risk of disease progression [J ] . Hepatology ， 2016 ， 64 （ 2 ）： 381 - 389 .

Yang Y ， Gao J ， Tan YT ， et al . Individual and combined effects of hepatitis B surface antigen level and viral load on liver cancer risk [J ] . J Gastroenterol Hepatol ， 2018 ， 33 （ 5 ）： 1131 - 1137 .

Zhou X ， Wuchter P ， Egerer G ， et al . Role of virological serum markers in patients with both hepatitis B virus infection and diffuse large B-cell lymphoma [J ] . Eur J Haematol ， 2019 ， 103 （ 4 ）： 410 - 416 .

Zhang MY ， Gao F ， Zhao YW ， et al . Inferior survival and frequent hepatic dysfunction in non-Hodgkin's lymphoma patients with HBV infection：a systematic review and Meta-analysis [J ] . Hematology ， 2022 ， 27 （ 1 ）： 70 - 79 .

Hu SF ， Chen N ， Lu K ， et al . The effect of hepatitis B virus antibody on clinical outcome and prognosis in patients with diffuse large B-cell lymphoma [J ] . Blood ， 2019 ， 134 ( Suppl 1 )： 4134 - 4134 .

Ren W ， Ye X ， Su H ， et al . Genetic landscape of hepatitis B virus-associated diffuse large B-cell lymphoma [J ] . Blood ， 2018 ， 131 （ 24 ）： 2670 - 2681 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

A real-world cohort study of antiviral therapy for reducing hepatocellular carcinoma risk in patients with chronic hepatitis B virus infection

Clinical role of von Willebrand factor antigen in HBV-related liver diseases

Quantification of intrahepatic cccDNA,DNA,serum HBV DNA and its relationship with HBeAg in hepatitis B virus-related hepatocellular carcinoma

S gene variations of hepatitis B virus in children with vaccination failure

Association between intrahepatic levels and mutation of hepatitis B virus covalently closed circular DNA in hepatitis B virus-related hepatocellular carcinoma

Related Author

Fu Maolan

Zhang Xuqing

Cheng Yu

Yu Shuang

Dai Zhenyu

Jiang Tingting

Bai Ying

Huang Jiajia

Related Institution

Department of Infectious Diseases，The Third Affiliated Hospital of Chongqing Medical University

School of Laboratory Medicine，Chongqing Medical University

Department of Joint and Sports Traumatology，Chongqing Liangjiang New Area Hospital of Traditional Chinese Medicine

Department of Laboratory Medicine，The Second Affiliated Hospital of Chongqing Medical University

Key Laboratory of Molecular Biology on Infectious Disease,Ministry of Education,Chongqing Medical University

⁰